Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-Seq of 2 lung metastatic breast cancer cell lines and their Nfib Kos.

ABSTRACT: Next Generation Sequencing was applied to investigate molecular mechanisms underlying the increased metastatic colonization driven by Nfib. Global transcriptional profiling of the lung metastatic cell lines and respective KOs allowed to identify Ero1l as a mediator of metastasis upon Nfib upregulation.

ORGANISM(S): Mus musculus

PROVIDER: GSE144393 | GEO | 2021/01/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

RNA-Seq of 3 breast cancer models to investigate NFIB signalling role in metastatic colonization.

Project description:Next Generation Sequencing was applied to investigate molecular mechanisms underlying the increased metastatic colonization driven by Nfib. Global transcriptional profiling of primary tumours derived from Nfib high-expression models (LM1 and LM9) and Nfib low-expression models (HR1) allowed to identify Ero1l as a mediator of metastasis upon Nfib upregulation.

2021-01-15 | GSE144392 | GEO

RNA-Seq of 2 lung metastatic breast cancer cell lines and their Nfib Kos.

Project description:RNA-Seq of 2 lung metastatic breast cancer cell lines and their Nfib Kos.

| PRJNA603549 | ENA

NFIB is a driver of SCLC initiation, progression and metastasis in mouse and marks metastatic disease in patients

Project description:Small Cell Lung Cancer (SCLC) is the most aggressive type of lung cancer with early metastatic dissemination and invariable development of resistant disease for which no effective treatment is available to date. Mouse models of SCLC based on inactivation of Rb1 and Trp53 developed earlier showed frequent amplifications of two transcription factor genes: Nfib and Mycl. Overexpression of Nfib but not Mycl in SCLC mouse results in an enhanced and altered metastatic profile, and appears to be associated with genomic instability. NFIB promotes tumor heterogeneity with the concomitant expansive growth of poorly differentiated, highly proliferative, and invasive tumor cell populations. Consistent with the mouse data, NFIB expression in high-grade human neuroendocrine carcinomas correlates with advanced stage III/IV disease warranting its further assessment as a potentially valuable progression marker in a clinical setting. Genomic DNA from mouse small cell lung tumor samples was analyzed by mate pair sequencing and low coverage sequencing. And RNA from Nfib overexpressing mouse small cell lung cancer cell lines was further analyzed for high quality RNA profiles using Illumina Hiseq2500. This series contains only RNA-seq data.

2016-07-29 | E-GEOD-82005 | biostudies-arrayexpress

NFIB is a driver of SCLC initiation, progression and metastasis in mouse and marks metastatic disease in patients

2016-07-29 | GSE82005 | GEO

RNA-Seq of 3 breast cancer models to investigate NFIB signalling role in metastatic colonization.

Project description:RNA-Seq of 3 breast cancer models to investigate NFIB signalling role in metastatic colonization.

| PRJNA603550 | ENA

Hypoxia-driven alterations in the B16 melanoma cell transcriptome account for a higher metastatic potential

Project description:Hypoxia-driven alterations in the B16 melanoma cell transcriptome account for a higher metastatic potential: evidence for a role of Ero1L We analyzed transcriptomic adaptations to hypoxia/reoxygenation in B16 melanoma cells. By Ero1L over- and down-expression in vivo, we identified this ER oxidase as an actor of tumor growth and metastasis take. In vitro culture of B16 submitted to hypoxia (oxygen rate less than 1%)

2013-08-01 | E-GEOD-14727 | biostudies-arrayexpress

Hypoxia-driven alterations in the B16 melanoma cell transcriptome account for a higher metastatic potential

2013-08-01 | GSE14727 | GEO

The NFIB/CARM1 Axis is a Therapeutic Target for Small Cell Lung Cancer

Project description:We identified NFIB as a CARM1 substrate and showed that this transcription factor utilizes CARM1 as a coactivator. Importantly, NFIB harbors both oncogenic and metastatic activities, and is often overexpressed in small cell lung cancer (SCLC). Using a SCLC mouse model, we show that both CARM1 and the CARM1 methylation site on NFIB are critical for the rapid onset of SCLC. By performing the high-throughput sequecing analysis, we found that CARM1-null and NFIB-R388K mutant mouse SCLC tumors share the ability to regulate chromatin accessbility and have similar gene expression pattern.

2022-02-07 | GSE195843 | GEO

Identifying NFIB target genes in mammalian cells

Project description:NFIB is a transcription factor that can both positively and negatively regulate gene transcription. We have identified NFIB as an arginine methylation substrate of CARM1. To elucidate how CARM1 could regulate NFIB target genes by methylating NFIB, we performed this ChIP-seq to firstly identify NFIB direct binding gengs.

2022-12-15 | GSE219265 | GEO

The NFIB/CARM1 Partnership is a Therapeutic Target for Small Cell Lung Cancer

Project description:This project identified NFI family members as CARM1 substrates. NFIB was previously reported to play a critical role in the development of small cell lung cancer. We provided evidence that the arginine methylation of NFIB is required for its oncogenic function in small cell lung cancer.

2023-02-07 | PXD038237 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data